Linked Life Data

19513296

Source:http://linkedlifedata.com/resource/pubmed/id/19513296

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2009-6-10
pubmed:abstractText
A carboxy-O-methyl transferase inhibitor entacapone has been introduced as an adjuvant drug for Parkinson disease (PD) patients. Although clinical trials reported beneficial role of entacapone, a long-term trial over 3 years failed to show significant effect. The goals of this study were to evaluate the clinical benefit and the efficacy of entacapone in an open clinical practice.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:status
PubMed-not-MEDLINE
pubmed:month
Jun
pubmed:issn
1738-6586
pubmed:author
pubmed:issnType
Print
pubmed:volume
3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
82-5
pubmed:year
2007
pubmed:articleTitle
One-year open-label study of entacapone in patients with advanced Parkinson disease.
pubmed:affiliation
Department of Neurology, Kyung Hee University College of Medicine, Korea.
pubmed:publicationType
Journal Article